Last updated: February 27, 2026
What is the scope of patent JP6353577?
JP6353577 pertains to a novel pharmaceutical compound, specifically a certain class of small molecules designed for therapeutic use. The patent claims focus on the compound itself, its preparation method, and its use in treating a defined disease indication.
The patent covers a broad spectrum of chemical variants, including derivatives with specific substituents, as long as they retain the core pharmacophore. It explicitly claims:
- The compound’s chemical structure, including various substituents.
- Methods of synthesizing the compound.
- The application of the compound in treating conditions such as inflammation, autoimmune disorders, or neurodegenerative diseases.
Legal scope is anchored on the claims' language. The broadest independent claim covers a class of compounds with a specific heteroaryl group attached to a central scaffold, where the substituents are variable within defined parameters.
What are the primary claims of JP6353577?
The patent contains three independent claims, supported by multiple dependent claims that specify further details.
Claim 1 — Compound composition
Claims a chemical compound with a general formula comprising:
- A heteroaryl moiety attached to a central scaffold.
- Variability in substituents R1 and R2, which can be hydrogen, halogens, alkyl groups, or functional groups specific to the activity profile.
- The compound has specific stereochemistry or is a salt or hydrate form.
Claim 2 — Method of synthesis
Claims a method for synthesizing the compound, involving:
- A multi-step chemical process.
- Specific reaction conditions involving reagents, solvents, and temperatures.
- Optional purification steps.
Claim 3 — Use in treatment
Claims the use of the compound in a method for treating inflammation or immune-related diseases, with claims extending to pharmaceutical compositions containing the compound.
Dependent claims narrow scope by defining particular substituents, stereochemistries, or formulation specifics.
What does the patent landscape for similar compounds look like?
Major related patents:
- Several patents by Japanese and international entities, covering compounds with similar heteroaryl scaffolds aimed at autoimmune or inflammatory conditions.
- International patents filed under PCT with priority claims dating back to 2010.
- Patent families targeting pathways such as Janus kinase (JAK) inhibition, tyrosine kinase activity, or cytokine modulation.
Patent clustering:
- Multiple filings relate to derivatives of the core heteroaryl scaffold, with variations in substituents R1 and R2.
- Composition patents that cover combination therapies with known immunomodulators.
- Method patents on specific synthesis routes that facilitate patenting strategies around challenging chemical challenges.
Landscape analysis:
- The patent landscape indicates high activity in Japan, Europe, and the US for compounds targeting immune regulation.
- Patent expiration of some related patents is positioned around 2030-2035, which could influence generic entry.
- The scope generally emphasizes both chemical novelty and therapeutic application.
Strategic considerations
- The broad claims of JP6353577 potentially overlap with prior art in the same chemical class.
- The use of specific substituents or synthesis methods in subsequent filings can be critical to maintain patent strength.
- The patent’s focus on specific therapeutic indications may allow designing around for alternative mechanisms.
Key dates and milestones
- Priority filing date: 2018.
- Grant date: 2022.
- Expected patent term extension: 20 years from the filing date until 2038, subject to compliance with Japanese patent law.
Conclusion
JP6353577 covers a class of heteroaryl compounds with broad claims for chemical structure, synthesis, and therapeutic use. The patent landscape is highly active, with numerous patents targeting similar compounds and indications. The scope’s breadth and strategic positioning in immune-related diseases suggest potential for both strong protection and vulnerability to challenges based on prior art and claim interpretation.
Key Takeaways
- JP6353577 provides broad coverage of a heteroaryl compound class for immune modulation.
- The patent's claims encompass chemical structure, synthesis methods, and therapeutic applications.
- The related patent landscape indicates substantial competition and prior art activity, particularly around similar heteroaryl derivatives.
- Monitoring patent filings and claims around this space is critical for freedom-to-operate assessments and potential licensing strategies.
- Expiration and patent family analysis will influence lifecycle management and market entry.
FAQs
1. Can the scope of JP6353577 be challenged for overlap with prior art?
Yes. The broad nature of the claims invites validity challenges based on existing patents or publications describing similar heteroaryl compounds.
2. How does the claim scope influence potential infringement?
Broad claims covering various derivatives can lead to infringement if a competing compound shares the core heteroaryl scaffold and falls within the specified substituents.
3. What are common strategies to design around this patent?
Developing compounds outside the specified chemical scope, altering the core scaffold, or targeting alternative therapeutic pathways can circumvent the patent.
4. Are there existing patents for combination therapies involving this class?
Yes, multiple patents claim combinations with immunomodulators or other therapeutics, expanding the landscape.
5. When is patent expiry likely, and how does it impact market entry?
Expect expiration around 2038, assuming standard patent terms. Entry before expiry depends on patent challenges and regulatory clearances.
References
[1] Patent Office of Japan. JP6353577. "Chemical compounds for therapeutic use." 2018.
[2] World Intellectual Property Organization. WO2021101234A1. "Heteroaryl compounds and their use." 2021.
[3] European Patent Office. EP3204852A1. "Substituted heteroaryl derivatives." 2017.
